Is this you? Create Your Porfile
Avatar

Thomas Haeder

ImmunoGen, Inc.

Network

Latest external collaboration on country level. Dive into details by clicking on the dots.

Explore More

Hotspot

Dive into the research topics where Thomas Haeder is active.

Explore More

Publication

Featured researches published by Thomas Haeder.

Blood | 2012

BT062, an Antibody-Drug Conjugate Directed Against CD138, Given Weekly for 3 Weeks in Each 4 Week Cycle: Safety and Further Evidence of Clinical Activity

Leonard T. Heffner; Sundar Jagannath; Todd M. Zimmerman; Kelvin P. Lee; Jacalyn Rosenblatt; Sagar Lonial; Robert J. Lutz; Niklas Czeloth; Frank Osterroth; Markus Ruehle; Michelle A. Beelitz; Andrea Wartenberg-Demand; Thomas Haeder; Kenneth C. Anderson; Nikhil C. Munshi

Blood | 2014

Indatuximab Ravtansine (BT062) in Combination with Lenalidomide and Low-Dose Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma: Clinical Activity in Patients Already Exposed to Lenalidomide and Bortezomib

Kevin R. Kelly; Asher Chanan-Khan; Leonard T. Heffner; George Somlo; David Siegel; Todd M. Zimmerman; Anand B. Karnad; Nikhil C. Munshi; Sundar Jagannath; Allen L. Greenberg; Sagar Lonial; Vivek Roy; Sikander Ailawadhi; Farima Barmaki-Rad; Shailesh Chavan; Pankaj Patel; Andrea Wartenberg-Demand; Thomas Haeder; Kenneth C. Anderson

Blood | 2011

BT062, An Antibody-Drug Conjugate Directed Against CD138, Shows Clinical Activity in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma

Sundar Jagannath; Asher Chanan-Khan; Leonard T. Heffner; David Avigan; Todd M. Zimmerman; Sagar Lonial; Robert J. Lutz; Andre Engling; Christoph Uherek; Frank Osterroth; Markus Ruehle; Michelle A. Beelitz; Gabriele Niemann; Andrea Wartenberg-Demand; Thomas Haeder; Kenneth C. Anderson; Nikhil C. Munshi

Blood | 2009

Phase I Study of BT062 Given as Repeated Single Dose Once Every 3 Weeks in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma.

Asher Chanan-Khan; Sundar Jagannath; Leonard T. Heffner; David Avigan; Kelvin P. Lee; Robert J. Lutz; Thomas Haeder; Markus Ruehle; Christoph Uherek; Andrea Wartenberg-Demand; Nikhil C. Munshi; Kenneth C. Anderson

Blood | 2013

Indatuximab Ravtansine (BT062) In Combination With Lenalidomide and Low-Dose Dexamethasone In Patients With Relapsed and/Or Refractory Multiple Myeloma: Clinical Activity In Len/Dex-Refractory Patients

Asher Chanan-Khan; George Somlo; Leonard T. Heffner; David Siegel; Todd M. Zimmerman; Sundar Jagannath; Nikhil C. Munshi; Sagar Lonial; Vivek Roy; Markus Ruehle; Shailesh Chavan; Pankaj Patel; Markus Rothenburger; Andrea Wartenberg-Demand; Thomas Haeder; Kenneth C. Anderson

Archive | 2010

USES OF IMMUNOCONJUGATES TARGETING CD138

Gregor Schulz; Frank Osterroth; Thomas Haeder; Christoph Bruecher; Gabriele Niemann; Andre Engling; Christoph Uherek; Benjamin Daelken; Andrea Wartenberg-Demand; Chantal Zuber; Marcus Gutscher; Katrin Bernoester; Martin Koenig

Blood | 2016

Indatuximab Ravtansine (BT062) in Combination with Low-Dose Dexamethasone and Lenalidomide or Pomalidomide: Clinical Activity in Patients with Relapsed / Refractory Multiple Myeloma

Kevin R. Kelly; David Siegel; Asher Chanan-Khan; George Somlo; Leonard T. Heffner; Sundar Jagannath; Todd M. Zimmerman; Nikhil C. Munshi; Sumit Madan; Ann Mohrbacher; Sagar Lonial; Farima Barmaki-Rad; Markus Rühle; Eva Herrmann; Andrea Wartenberg-Demand; Thomas Haeder; Kenneth C. Anderson

Blood | 2010

BT062, An Antibody-Drug Conjugate Directed Against CD138, Shows Clinical Activity In a Phase I Study In Patients with Relapsed or Relapsed/Refractory Multiple Myeloma

Sundar Jagannath; Asher Chanan-Khan; Leonard T. Heffner; David Avigan; Robert J. Lutz; Christoph Uherek; Frank Osterroth; Markus Ruehle; Thomas Haeder; Gabriele Niemann; Andrea Wartenberg-Demand; Nikhil C. Munshi; Kenneth C. Anderson

Blood | 2010

BT062, a CD138-Specific Immunoconjugate, Demonstrates Superior In Vivo Anti-Myeloma Efficacy In Combination with Lenalidomide or Bortezomib

Chantal Zuber; Benjamin Daelken; Silke Aigner; Thomas Haeder; Olga Ab; Kathleen R. Whiteman; Teru Hideshima; Robert J. Lutz; Frank Osterroth; Christoph Uherek

Archive | 2017

método para tratar uma doença, e, kit

Andre Engling; Andrea Wartenberg-Demand; Benjamin Daelken; Chantal Zuber; Christoph Bruecher; Christoph Uherek; Frank Osterroth; Gabriele Niemann; Gregor Schulz; Katrin Bernoester; Marcus Gutscher; Martin Koenig; Thomas Haeder

Explore More

Collaboration

Dive into the Thomas Haeder's collaboration.

Top Co-Authors
Avatar

Andrea Wartenberg-Demand

ImmunoGen

View shared research outputs
Top Co-Authors
Avatar

Frank Osterroth

Harvard University

View shared research outputs
Top Co-Authors
Avatar

Kenneth C. Anderson

Harvard University

View shared research outputs
Top Co-Authors
Avatar

Leonard T. Heffner

Emory University

View shared research outputs
Top Co-Authors
Avatar

Nikhil C. Munshi

Harvard University

View shared research outputs
Top Co-Authors
Avatar

Sundar Jagannath

Mount Sinai Hospital

View shared research outputs
Top Co-Authors
Avatar

Christoph Uherek

Goethe University Frankfurt

View shared research outputs
Top Co-Authors
Avatar

Asher Chanan-Khan

Mayo Clinic

View shared research outputs
Top Co-Authors
Avatar

Gabriele Niemann

ImmunoGen

View shared research outputs
Top Co-Authors
Avatar

Andre Engling

ImmunoGen

View shared research outputs
Explore More
Researchain Logo
Decentralizing Knowledge